title: [Adjuvant chemotherapy of non-small cell lung cancer: Tolerance of combined cisplatin-pemetrexed therapy].
abstract: BACKGROUND
  Adjuvant chemotherapy is standard for non-small cell lung cancer (NSCLC) after surgical resection. In this context, the tolerance of the treatment is an essential criterion in the choice of chemotherapy. This exploratory study evaluated, in the situation of adjuvant chemotherapy, the tolerance of combined cisplatin-pemetrexed. The study analyzed a cohort of non-squamous NSCLC patients treated in an adjuvant setting by combined cisplatin (75 mg/m(2)) and pemetrexed (500 mg/m(2)), under vitamin B12 and folic acid cover, 4 cycles at 21-day intervals.
  
  
  RESULTS
  The analysis included 23 patients (age: 58.7 ± 5 years, men: 56%, average creatinin clearance (Clea): 94 ± 22 mL/min, average haemoglobin: 13.8 ± 1.6g/dL). Over 92 planned courses, 7.6% are postponed (neutropenia), 4.3% were not given (asthenia). We noted 7 episodes of vomiting (4 grade 3), with two hospitalizations in the same patient; 5 episodes of anaemia grade 1-2 not requiring EPO prescription or transfusion and no febrile neutropenia. At the end of the treatment, three patients had a Clea<50 mL/mn and 5 a haemoglobin between 9 and 11 g/dL.
  
  
  CONCLUSIONS
  Combined cisplatin-pemetrexed in an adjuvant situation has a satisfactory tolerance.
authors.affiliation: Service de pneumologie, hôpital Saint-Antoine, AP-HP, 75012 Paris, France.
authors.forename: C
authors.initials: C
authors.lastname: Gauvain
authors.affiliation: Service de pneumologie, hôpital Saint-Antoine, AP-HP, 75012 Paris, France.
authors.forename: P
authors.initials: P
authors.lastname: Crequit
authors.affiliation: Service de pneumologie, hôpital Saint-Antoine, AP-HP, 75012 Paris, France.
authors.forename: G
authors.initials: G
authors.lastname: Rousseau-Bussac
authors.affiliation: Service de pneumologie, hôpital Saint-Antoine, AP-HP, 75012 Paris, France.
authors.forename: A
authors.initials: A
authors.lastname: Ganoun
authors.affiliation: Service de pneumologie, hôpital Saint-Antoine, AP-HP, 75012 Paris, France.
authors.forename: M
authors.initials: M
authors.lastname: Baud
authors.affiliation: Service de pneumologie, hôpital Saint-Antoine, AP-HP, 75012 Paris, France; Service de pneumologie, centre hospitalier intercommunal de Créteil, 40, avenue de Verdun, 94010 Créteil, France. Electronic address: Christos.chouaid@chicreteil.fr.
authors.forename: C
authors.initials: C
authors.lastname: Chouaid
mesh_terms: D000368:Aged; D000740:Anemia / Q000139:chemically induced / Q000453:epidemiology; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000453:epidemiology / Q000473:pathology; D017024:Chemotherapy, Adjuvant; D002945:Cisplatin / Q000008:administration & dosage / Q000009:adverse effects; D005260:Female; D005971:Glutamates / Q000008:administration & dosage / Q000009:adverse effects; D006147:Guanine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives*; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000453:epidemiology / Q000473:pathology; D008297:Male; D008875:Middle Aged; D009503:Neutropenia / Q000139:chemically induced / Q000453:epidemiology; D000068437:Pemetrexed; D012189:Retrospective Studies
chemical_list: D005971:Glutamates; D000068437:Pemetrexed; D006147:Guanine; D002945:Cisplatin
keywords: Adjuvant chemotherapy; Cancer bronchique; Chimiothérapie adjuvante; Cisplatin; Cisplatine; Lung cancer; Pemetrexed; Tolerance; Tolérance